Results 11 to 20 of about 48,174 (231)
Is a QALY still a QALY at the end of life?
Journal of Health Economics, 2012 Recent research into end of life and palliative care has focused on the development of a replacement for the quality adjusted life year (QALY) as an outcome measure. Reasons given range from the lack of anticipated survival benefit from treatment to the inappropriateness of death as an anchor for valuing health states, or the increased value of time to
Round, Jeff, Jeff Round
openaire +4 more sources
Abandoning Eugenics and the QALY
INNOVATIONS in Pharmacy, 2021 Should decision making in health care, notably in respect of the allocation of resources between individuals and disease states, rest on notions of the burden of disease and denial of care as assessed by societal evaluations or on the extent to which the
Paul C Langley
doaj +4 more sources
Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States [PDF]
Human Vaccines & ImmunotherapeuticsImmunotherapy‑based combination regimens provide significant clinical benefits but impose substantial economic burdens on national healthcare systems. This study assessed the cost-effectiveness of immunotherapy‑based combination regimens as first-line ...
Chunyan Yan +5 more
doaj +2 more sources
Health Economics, 2003 Abstract A willingness to pay (WTP) per quality‐adjusted‐life year (QALY) of DKK 88 was estimated on the basis of elicited preferences for health states. The WTP per QALY estimate presented here differs considerably from that implied in contingent valuation studies, suggesting that WTP for reducing risk of death ...
Dorte Gyrd-Hansen, Gyrd-Hansen, D
openaire +8 more sources
A QALY loss is a QALY loss is a QALY loss: a note on independence of loss aversion from health states [PDF]
The European Journal of Health Economics, 2018 Evidence has accumulated documenting loss aversion for monetary and, recently, for health outcomes-meaning that, generally, losses carry more weight than equally sized gains. In the conventional Quality-Adjusted Life Year (QALY) models, which comprise utility for quality and length of life, loss aversion is not taken into account.
Stefan A. Lipman +2 more
openaire +4 more sources
Epidemiological and pharmacoeconomic aspects of HIV infection in military
Журнал инфектологии, 2021 The goals of the research are to determine the latent morbidity and financial losses of the Russian Ministry of Defense due to the dismissal of service members with HIV infection at symptomatic stages; to establish the supposed clinical and ...
Yu. I. Bulankov +6 more
doaj +1 more source
Modelling the Health Economic Impact of Influenza Vaccination Strategies for High-Risk Children in Vietnam [PDF]
Journal of Clinical and Diagnostic Research, 2018 Introduction: In Vietnam, since 2011 a National Influenza Surveillance System in Vietnam has implemented Severe Acute Respiratory Infection (SARI) surveillance to assemble information and inform administrational and methods of prevention.
Trung Quang Vo +3 more
doaj +1 more source
Health and Quality of Life Outcomes, 2015 Measuring health and health-related quality of life (HRQoL) is important for tracking the health of individuals and populations over time. Generic HRQoL measures allow for comparison across health conditions. One form of generic HRQoL measures are profile measures, which provide a description of health across several different domains (such as physical
Janel Hanmer +9 more
openaire +4 more sources
“The trouble with QALYs…” [PDF]
Epidemiology and Psychiatric Sciences, 2007 AbstractThis paper summarises the use of QALYs in evaluating changes in mental health states, highlighting the benefits and challenges of their use in this field. The general principles underlying the QALY measure and the most common methods of measuring QALYs are discussed briefly.
Knapp, M, Mangalore, R
openaire +2 more sources
QJM, 2010 Current regulation of drug approvals has caused considerable controversy as entrusted to the National Institute of Clinical Excellence, and has led to a lack of availability of modern medicines on the basis of calculations made of 'value'.We have examined the assessment tool used by National Institute of Clinical Excellence (NICE) to establish the cost
R, Kirkdale +4 more
openaire +2 more sources